Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose
Completed
Bayer
Phase 4
2018-11-14
The study was conducted to gain knowledge about a new dose of a diagnostic drug that is used
for contrast-enhanced Magnetic Resonance Imaging (MRI) of the human central nervous system
(CNS). MRI can visualize the anatomy of the body and is used to detect medical conditions.
Diagnostic drugs like gadobutrol and gadoterate contain an element called gadolinium that is
applied to improve the analysability of MRI-images.
The purpose of this study was to examine if contrast-enhanced MRI using a reduced dose of the
gadolinium-based contrast agent gadobutrol delivers images of similar quality to those
obtained when a full dose of the gadolinium-based contrast agent gadoterate was used.
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Completed
Guerbet
Phase 4
2008-01-01
Although there is a well documented risk of acute renal failure with the iodinated contrast
agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity
remains controversial. The aim of this study was to evaluate the safety profile of gadoterate
meglumine (Dotarem®) in patients with chronic renal insufficiency by evaluating the rate of
patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate
meglumine.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
